CN108601757A - 治疗和/或预防急性肝功能衰竭和其它肝毒性病况的方法和制剂 - Google Patents

治疗和/或预防急性肝功能衰竭和其它肝毒性病况的方法和制剂 Download PDF

Info

Publication number
CN108601757A
CN108601757A CN201780006292.1A CN201780006292A CN108601757A CN 108601757 A CN108601757 A CN 108601757A CN 201780006292 A CN201780006292 A CN 201780006292A CN 108601757 A CN108601757 A CN 108601757A
Authority
CN
China
Prior art keywords
manganese
active agent
individual
pharmaceutically acceptable
dpdp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780006292.1A
Other languages
English (en)
Chinese (zh)
Inventor
雅克·纳斯特伦姆
斯文·杰克布森
丹尼斯·亨里克森
詹姆斯·范·阿尔斯廷
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Egetis Therapeutics AB
Original Assignee
Pledpharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pledpharma AB filed Critical Pledpharma AB
Publication of CN108601757A publication Critical patent/CN108601757A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201780006292.1A 2016-01-11 2017-01-10 治疗和/或预防急性肝功能衰竭和其它肝毒性病况的方法和制剂 Pending CN108601757A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662277232P 2016-01-11 2016-01-11
US62/277,232 2016-01-11
US201662361605P 2016-07-13 2016-07-13
US62/361,605 2016-07-13
PCT/IB2017/050115 WO2017122120A1 (en) 2016-01-11 2017-01-10 Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions

Publications (1)

Publication Number Publication Date
CN108601757A true CN108601757A (zh) 2018-09-28

Family

ID=57909814

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780006292.1A Pending CN108601757A (zh) 2016-01-11 2017-01-10 治疗和/或预防急性肝功能衰竭和其它肝毒性病况的方法和制剂

Country Status (8)

Country Link
US (2) US11260060B2 (enExample)
EP (2) EP3402475B1 (enExample)
JP (2) JP7311267B2 (enExample)
CN (1) CN108601757A (enExample)
AU (1) AU2017208123B2 (enExample)
CA (1) CA3010915C (enExample)
RU (1) RU2018128793A (enExample)
WO (1) WO2017122120A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11260060B2 (en) * 2016-01-11 2022-03-01 Egetis Therapeutics Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
CN111372596A (zh) 2017-08-30 2020-07-03 潘德勒姆治疗公司 用于治疗微生物组相关病症的方法和组合物
RU2693677C1 (ru) * 2018-10-15 2019-07-03 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ гемокоррекции при лечении печеночной недостаточности
US20220211780A1 (en) * 2019-05-21 2022-07-07 Pendulum Therapeutics, Inc. Methods And Compositions For Treating Liver Disorders
WO2022269026A1 (en) 2021-06-25 2022-12-29 Forschungsgesellschaft Für Arbeitsphysiologie Und Arbeitsschutz E. V. Treating acetaminophen overdose
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087579A1 (fr) * 2001-04-26 2002-11-07 Universite Rene Descartes (Paris V) Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
US20120101066A1 (en) * 2009-07-06 2012-04-26 Jan-Olof Karlsson Pharmaceutical Compositions and Therapeutic Methods Employing a Combination of a Manganese Complex Compound and a Non-Manganese Complex Form of the Compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566401B2 (en) 2001-03-30 2003-05-20 The Board Of Trustees Of The Leland Stanford Junior University N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
WO2005017094A2 (en) 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
US20090234011A1 (en) 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress
AU2007308742A1 (en) 2006-10-23 2008-05-02 The Mental Health Research Institute Of Victoria Combination therapy
US20080139654A1 (en) * 2006-12-09 2008-06-12 Eric Mott Soderling Acetaminophen compositions having minimized side effects including reduced hepatotoxicity
CN107353313B (zh) * 2012-01-05 2019-04-09 普莱制药公司 新化学实体钙锰福地吡和其他混合金属配合物、制备方法、组合物以及治疗方法
US20140178358A1 (en) * 2012-12-21 2014-06-26 The United States of America as represented by the Secretary of Department of Health and Human Servi Means and Methods to Diagnose Liver Toxicity using Putrescine as Biomarker
US11260060B2 (en) 2016-01-11 2022-03-01 Egetis Therapeutics Ab Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002087579A1 (fr) * 2001-04-26 2002-11-07 Universite Rene Descartes (Paris V) Utilisation du mangafodipir dans le traitement des effets d'un stress oxydatif
US20120101066A1 (en) * 2009-07-06 2012-04-26 Jan-Olof Karlsson Pharmaceutical Compositions and Therapeutic Methods Employing a Combination of a Manganese Complex Compound and a Non-Manganese Complex Form of the Compound

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ROBERT J. FONTANA, MD: "Acute Liver Failure Including Acetaminophen Overdose", 《MED CLIN N AM》 *

Also Published As

Publication number Publication date
JP2022019973A (ja) 2022-01-27
US12303516B2 (en) 2025-05-20
US20190015424A1 (en) 2019-01-17
JP2019501226A (ja) 2019-01-17
RU2018128793A3 (enExample) 2020-05-25
EP3402475A1 (en) 2018-11-21
US20220133739A1 (en) 2022-05-05
JP7311267B2 (ja) 2023-07-19
AU2017208123B2 (en) 2022-04-21
JP7374163B2 (ja) 2023-11-06
US11260060B2 (en) 2022-03-01
WO2017122120A1 (en) 2017-07-20
CA3010915C (en) 2024-06-04
EP3842040A1 (en) 2021-06-30
EP3842040B1 (en) 2022-03-09
EP3402475B1 (en) 2021-10-20
AU2017208123A1 (en) 2018-07-19
RU2018128793A (ru) 2020-02-13
CA3010915A1 (en) 2017-07-20

Similar Documents

Publication Publication Date Title
US12303516B2 (en) Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
Fishbane N-acetylcysteine in the prevention of contrast-induced nephropathy
Fishbane et al. N-acetylcysteine in the prevention of radiocontrast-induced nephropathy
Mohiuddin et al. Biochemistry, ammonia
Ganz et al. Mechanism of action and clinical attributes of Auryxia®(ferric citrate)
Hristov The role of glutathione metabolism in chronic illness development and its potential use as a novel therapeutic target
US20050070607A1 (en) N-acetylcysteine compositions and methods for the treatment and prevention of cysteine/glutathione deficiency in diseases and conditions
CN103038356A (zh) 乙酰半胱氨酸组合物及其使用方法
Dohil et al. Twice-daily cysteamine bitartrate therapy for children with cystinosis
Jeon et al. Comparison of vildagliptin-metformin and glimepiride-metformin treatments in type 2 diabetic patients
Demiroren et al. A comparison of the effects of thymoquinone, silymarin and N-acetylcysteine in an experimental hepatotoxicity
Leira et al. Uric acid: a translational journey in cerebroprotection that spanned preclinical and human data
Shalansky et al. N‐acetylcysteine for Prevention of Radiographic Contrast Material–Induced Nephropathy: Is the Intravenous Route Best?
Rahimi et al. Novel ammonia-lowering agents for hepatic encephalopathy
CN108883085A (zh) 用铁化合物和柠檬酸盐化合物的组合物疗法
Smith Drugs and pharmaceuticals: management of intoxication and antidotes
Patel et al. Amlodipine overdose
CN104619316B (zh) 用于降低n-氧化三甲胺水平的药物组合物
HK40056482A (en) Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
HK40056482B (en) Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
KR20220130253A (ko) 안정한 글루코코르티코이드 제제
Worland et al. Gastric and intestinal absorption of captopril in acutely and chronically treated rats: comparison with salicylic acid
HK1260784B (en) Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
Tan et al. Acute kidney injury and iron metabolism: A narrative review focusing on pathophysiology and therapy
Oliveira N-Acetylcysteine (nac): impacts on human health

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Stockholm, Sweden

Applicant after: Iqitis treatment Co.

Address before: Stockholm, Sweden

Applicant before: PLEDPHARMA AB

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20180928

RJ01 Rejection of invention patent application after publication